Peptide-22 and Cyclic RGD Functionalized Liposomes for Glioma Targeting Drug Delivery Overcoming BBB and BBTB.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Peptide-22 and Cyclic RGD Functionalized Liposomes for Glioma Targeting Drug Delivery Overcoming BBB and BBTB.
- Published In:
- ACS applied materials & interfaces, 9(7), 5864-5873 (2017)
- Authors:
- Chen, Cuitian, Duan, Ziqing, Yuan, Yan, Li, Ruixiang, Pang, Liang, Liang, Jianming, Xu, Xinchun, Wang, Jianxin
- Database ID:
- RPEP-03235
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-03235APA
Chen, Cuitian; Duan, Ziqing; Yuan, Yan; Li, Ruixiang; Pang, Liang; Liang, Jianming; Xu, Xinchun; Wang, Jianxin. (2017). Peptide-22 and Cyclic RGD Functionalized Liposomes for Glioma Targeting Drug Delivery Overcoming BBB and BBTB.. ACS applied materials & interfaces, 9(7), 5864-5873. https://doi.org/10.1021/acsami.6b15831
MLA
Chen, Cuitian, et al. "Peptide-22 and Cyclic RGD Functionalized Liposomes for Glioma Targeting Drug Delivery Overcoming BBB and BBTB.." ACS applied materials & interfaces, 2017. https://doi.org/10.1021/acsami.6b15831
RethinkPeptides
RethinkPeptides Research Database. "Peptide-22 and Cyclic RGD Functionalized Liposomes for Gliom..." RPEP-03235. Retrieved from https://rethinkpeptides.com/research/chen-2017-peptide22-and-cyclic-rgd
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.